An Investigational Immuno-Therapy Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

February 16, 2017

Primary Completion Date

November 27, 2017

Study Completion Date

June 15, 2021

Conditions
Renal Cell Carcinoma
Interventions
BIOLOGICAL

Opdivo

Specified dose on specified days

BIOLOGICAL

Yervoy

Specified dose on specified days

Trial Locations (11)

2145

Local Institution, Westmead

2298

Local Institution, Waratah

3144

Local Institution, Malvern

4029

Local Institution, Herston

5112

Local Institution, Elizabeth Vale

28204

Levine Cancer Institute, Charlotte

32256

Cancer Specialists of North FL, Jacksonville

52242

University Of Iowa Hospitals And Clinics, Iowa City

7500921

Fundacion Arturo Lopez Perez, Santiago

15212-0000

Local Institution, Pittsburgh

Unknown

Centro Internacional de Estudios Clinicos, Recoleta

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY